Trial Condition(s):
Pneumonia
CAPRIVI: Community Acquired Pneumonia: Treatment with Avelox® in Hospitalized Patients
Bayer Identifier:
14522
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The aim of this study is to obtain data from hospitalized Community Acquired Pneumonia (CAP) patients on the disease including disease severity, clinical signs and symptoms and measures used for diagnosis in daily routine practice as well as data on Avelox® including information on the use, effectiveness, treatment outcome, safety and tolerability.
As this is a non-interventional observational study, routine clinical practice is observed. The application of medications follows the normal routines and is decided by the treating physician under recognition of the package insert.
Inclusion Criteria
- Adult hospitalized patients with a diagnosis of CAP (based on local medical practice) and decision taken by the investigator to treat with moxifloxacin and to start treatment with intravenous administration. The local moxifloxacin product information must be considered.
Exclusion Criteria
- Contraindications stated in the local moxifloxacin product information; warnings and precautions must be considered.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Macedonia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Croatia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Moldova | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Kazakhstan | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Hungary | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Russia | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Ukraine | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Romania | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Jordan | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, Lebanon | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Many Locations, France | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
CAPRIVI: Community Acquired Pneumonia: Treatment with Avelox® in Hospitalized Patients
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- The primary objective is to evaluate the distribution of the CRB-65 severity index at baseline in hospitalized patients suffering from CAP and to whom moxifloxacin (starting with intravenous administration) was prescribed, in countries from South EasternTimeframe: At baseline only
Secondary Outcome
- Assessment of use of different diagnostic measures in daily routine practice, especially chest radiography and microbiologyTimeframe: 7-14 days
- Determination of the proportion of patients treated with moxifloxacin as antibiotic second-line therapyTimeframe: 7-14 days
- Assessment of clinical signs and symptoms before and after therapy with moxifloxacinTimeframe: 7-14 days
- Measurement of moxifloxacin treatment success in terms of effectiveness and outcomeTimeframe: 7-14 days
- Evaluation of safety and tolerability of moxifloxacin in hospitalized CAP patientsTimeframe: 7-14 days
Additional Information
Copyright © Bayer
Powered by
